Document Detail


Intrathecal Bupivacaine in Comparison With a Combination of Nalbuphine and Bupivacaine for Subarachnoid Block: A Randomized Prospective Double-Blind Clinical Study.
MedLine Citation:
PMID:  21904194     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
We performed this randomized, prospective double-blind study to evaluate the effects of 2 different doses of intrathecal nalbuphine (a synthetic opioid agonist-antagonist) on the onset, duration of action, side effects, and complication produced by intrathecal hyperbaric 0.5% bupivacaine in lower abdominal, urologic and lower limb surgeries. Seventy-five patients of ASA grades 1 and 2 of either sex in the age group of 20-60 years were randomly allocated to 1 of 3 groups. Group A (n = 25) received 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL sterile water intrathecally; group B (n = 25) received 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (200 μg) nalbuphine intrathecally; group C (n = 25) received 2.5 mL of 0.5% hyperbaric bupivacaine + 1 mL (400 μg) nalbuphine intrathecally. The onsets of sensory and motor blockade, highest level of sensory blockade, 2 segment regression time of sensory blockade, duration of motor blockade and analgesia, visual analog scale score, hemodynamic and respiratory changes, side effects were recorded, tabulated, and analyzed. Onsets of sensory and motor blockade and duration of motor blockade were not affected. Two segment regression time of sensory blockade and duration of analgesia were maximally prolonged in group C (P < 0.05). The visual analog scale scores were in the following order: group A > group B > group C at 90, 120, and 150 minutes after induction (P < 0.05). Hemodynamic and respiratory complications were absent except in 2 patients in groups A and C each, and 1 patient in group B developed bradycardia (P > 0.05). One patient in group A had nausea and vomiting, 2 patients in each group developed shivering (P > 0.05). No other side effect or complication was observed. Nalbuphine hydrochloride (400 μg) significantly prolongs the duration of sensory blockade and postoperative analgesia without any side effect or complication when introduced intrathecally along with hyperbaric bupivacaine.
Authors:
Akhilesh Kumar Tiwari; Gaurav Singh Tomar; Jeetendra Agrawal
Related Documents :
8924004 - Clinical experience in temporomandibular joint arthroscopy.
21622014 - Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective...
21884084 - Headache in 25 consecutive patients with atrial septal defects before and after percuta...
25419374 - Intraoperative systemic lidocaine inhibits the expression of hmgb1 in patients undergoi...
15049984 - The natural history of lower urinary tract dysfunction in men: the influence of detruso...
23817754 - Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patie...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-08
Journal Detail:
Title:  American journal of therapeutics     Volume:  -     ISSN:  1536-3686     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Department of Anaesthesia, Sushruta Trauma Centre, Delhi; and 2Department of Anaesthesia, G.R. Medical College, Gwalior, India. First and second authors contributed equally to this work.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Motor Factors Associated with Health-Related Quality-of-Life in Ambulatory Children with Cerebral Pa...
Next Document:  Biological Mitral Valve Prosthesis in a Patient Supported With a Permanent Left Ventricle Assist Dev...